文献速递自身炎症与 IgG4 相关病血管炎

IgG4相关冠状动脉受累:一项范围综述

IgG4 related coronary artery involvement: A scoping review of the literature.
PubMed 文献 · Semin Arthritis Rheum · 2026-01-23

该范围综述检索PubMed并纳入143篇文献,总结IgG4相关冠状动脉受累的临床、影像、病理特征及治疗预后。多数为病例报告,多见于男性第六十年,常合并主动脉及大血管受累,糖皮质激素联合或不联合免疫抑制剂及手术为最常见治疗,部分病例仍复发或进展。

要点

  • IgG4相关冠状动脉受累可累及冠状动脉各段,表现为狭窄、壁增厚、动脉瘤、扩张、假瘤、假性动脉瘤、夹层及软组织肿块。
  • 多数病例为病例报告,常合并主动脉及大血管受累,血清IgG4及炎症标志物可升高。
  • 糖皮质激素联合或不联合免疫抑制剂及手术为最常见治疗,利妥昔单抗可能有效,但部分病例仍复发或进展。

核心结论

  • 早期识别和多学科管理IgG4相关冠状动脉受累对降低发病率和死亡率至关重要。
  • 现有关于不同治疗反应的数据有限,因治疗后未及时一致地行冠状动脉影像评估,且并非所有患者均有长期随访。
  • 需进一步研究以了解该严重疾病的真实患病率、自然史、最佳诊断策略和治疗方案。

研究设计与样本

  • 范围综述,于2025年1月2日在PubMed检索描述IgG4相关冠状动脉受累(包括冠状动脉炎和冠状动脉周围炎)的研究,涵盖病例报告、病例系列、回顾性队列研究和观察性研究。
  • 由两名评审员在方法学家指导下独立筛选文献,提取临床表现、影像学、组织病理学、治疗和结局数据,因研究异质性尽可能采用描述性统计分析。
  • 共筛选964篇参考文献,最终143篇文章符合纳入标准。

主要发现

  • 大多数冠状动脉受累病例来自病例报告(90.2%),7%来自病例系列,2.8%来自回顾性队列研究或观察性研究。
  • 冠状动脉受累主要影响男性第六十年,常合并主动脉及大血管受累;冠状动脉树所有节段均可受累,甚至最小分支。
  • 多种影像方法检测到的病变类型包括狭窄、壁增厚、动脉瘤、扩张、假瘤、假性动脉瘤、夹层和软组织肿块。
  • 报告有血清IgG4水平升高和炎症标志物升高;所有获得的冠状动脉样本组织病理学均符合IgG4相关疾病。
  • 糖皮质激素单用或联合免疫抑制剂和/或手术干预是最常报告的治疗;利妥昔单抗似乎对IgG4相关冠状动脉受累有效,即使不联合糖皮质激素;尽管治疗,部分病例仍出现复发和冠状动脉病变进展。

临床怎么用

  • 对IgG4相关疾病患者应警惕冠状动脉受累,尤其合并主动脉及大血管受累的男性第六十年患者。
  • 诊断需结合临床表现、多种影像学检查(包括冠状动脉影像)及组织病理学,血清IgG4和炎症标志物可辅助评估。
  • 治疗以糖皮质激素为基础,可联合免疫抑制剂和/或手术干预;利妥昔单抗可作为治疗选择,即使不联合糖皮质激素。
  • 治疗后应适时行冠状动脉影像评估以判断反应,并注意长期随访监测复发和病变进展。

局限性

  • 大多数数据来自病例报告(90.2%),研究异质性大,仅采用描述性统计分析。
  • 治疗后未及时一致地行专用冠状动脉影像评估治疗反应,且并非所有患者均有长期随访。
  • 现有关于不同治疗反应的数据有限,真实患病率、自然史、最佳诊断策略和治疗方案尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immunoglobulin (Ig)G4-related disease (IgG4-RD) can affect any organ, but coronary artery involvement (CAI) is a potentially life-threatening manifestation of this disease. In this scoping review, we critically appraised the literature on IgG4-related CAI, aiming to explore clinical, radiological and histopathological characteristics as well as treatment strategies and prognosis. METHODS: A comprehensive search was performed on January 02, 2025 in PubMed® to identify studies describing individuals with IgG4-related CAI, including both coronaritis (true arteritis of the coronary vessel wall) and periarteritis (peri-coronary involvement), and considering case reports, case series, retrospective cohort studies and observational studies. Two reviewers independently conducted the revision of literature under the guidance of the methodologist to identify eligible studies. Data extraction included clinical presentation, imaging findings, histopathology, treatment, and outcomes. Given the heterogeneity of the studies, descriptive statistical analysis was used whenever possible to summarise the data. RESULTS: Out of 964 screened references, 143 articles met the above-mentioned inclusion criteria. Most CAI cases were included in case reports (90.2 %), 7 % in case series and 2.8 % in retrospective cohort studies or observational studies. CAI predominantly affected males in the sixth decade of life and frequently coexisted with aortic and large vessel involvement. All segments of the coronary arterial tree could be involved, even the smallest branches. Images detected by various methods revealed several types of lesions: stenosis, wall-thickening, aneurysm, ectasia, pseudotumor, pseudoaneurysm, dissection, and soft tissue masses. Increase serum IgG4 levels and increased inflammatory markers were reported. Histopathology was consistent with IgG4-RD in all coronary samples obtained. Glucocorticoid therapy, alone or combined with immunosuppressants and/or surgical interventions, was the most commonly reported treatment. Rituximab seemed to be an effective therapy for IgG4-related CAI even without associated glucocorticoids. Despite treatment, relapse and progression of coronary lesions were noted in some cases. CONCLUSIONS: Early identification and multidisciplinary management og IgG4-related CAI are crucial to reduce morbidity and mortality. Available data on the response to various treatments are limited, as dedicated coronary artery imaging was not consistently obtained soon enough after treatment to assess response. In addition, long-term follow-up was not available for all patients. Further studies are required to understand the real prevalence, natural history, optimal diagnostic strategies, and therapeutic approaches for this serious condition.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Carubbi F, Alunno A, Di Bartolomeo S, et al. IgG4 related coronary artery involvement: A scoping review of the literature. Semin Arthritis Rheum. 2026. PMID: 41616384. doi:10.1016/j.semarthrit.2026.152925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。